Thanks for sharing: RVV mentioned in article: "Revive Therapeutics (CAN: RVV / US: $RVVTF) plans to seek IND status from the FDA in Q2 2021, for its psilocybin-based research on TBI. With a different (non-psychedelic) drug already in a Phase III clinical trial, Revive has more experience in formal clinical research. But TBI is not the principal focus of its R&D."
Traumatic Brain Injury: Six Psychedelics Companies Target $120 Billion Market
Thanks for sharing: RVV mentioned in article: "Revive Therapeutics (CAN: RVV / US: $RVVTF) plans to seek IND status from the FDA in Q2 2021, for its psilocybin-based research on TBI. With a different (non-psychedelic) drug already in a Phase III clinical trial, Revive has more experience in formal clinical research. But TBI is not the principal focus of its R&D."